DexCom, Inc. (DXCM) Shares Sold by Sei Investments Co.

Sei Investments Co. lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 26.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 424,956 shares of the medical device company’s stock after selling 156,714 shares during the quarter. Sei Investments Co. owned 0.49% of DexCom worth $20,791,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its position in DexCom by 133.3% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 22,094 shares of the medical device company’s stock valued at $1,081,000 after buying an additional 12,623 shares during the last quarter. FDx Advisors Inc. raised its position in DexCom by 47.5% in the 3rd quarter. FDx Advisors Inc. now owns 17,307 shares of the medical device company’s stock valued at $847,000 after buying an additional 5,576 shares during the last quarter. Global X MANAGEMENT CO LLC raised its position in DexCom by 30.1% in the 3rd quarter. Global X MANAGEMENT CO LLC now owns 39,701 shares of the medical device company’s stock valued at $1,942,000 after buying an additional 9,185 shares during the last quarter. Pitcairn Co. raised its position in DexCom by 90.8% in the 3rd quarter. Pitcairn Co. now owns 29,958 shares of the medical device company’s stock valued at $1,466,000 after buying an additional 14,260 shares during the last quarter. Finally, Swiss National Bank raised its position in DexCom by 3.4% in the 3rd quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock valued at $15,578,000 after buying an additional 10,500 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This story was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.truebluetribune.com/2017/11/14/dexcom-inc-dxcm-shares-sold-by-sei-investments-co.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total value of $123,050.10. Following the completion of the sale, the executive vice president now owns 72,395 shares of the company’s stock, valued at $5,448,447.70. The disclosure for this sale can be found here. Insiders sold a total of 13,964 shares of company stock valued at $948,039 over the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

DexCom, Inc. (DXCM) opened at $51.55 on Tuesday. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80.

A number of equities research analysts recently issued reports on DXCM shares. Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub lowered DexCom from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $92.00 target price on DexCom and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Stephens reissued an “overweight” rating and issued a $83.00 target price (down previously from $95.00) on shares of DexCom in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $90.00 target price (down previously from $105.00) on shares of DexCom in a research report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and a consensus price target of $70.69.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply